Get started
Author

Anshu Kuriakose

ORCID: 0000-0001-5921-9734
Observed ORCID: 0000-0001-5921-9734
OpenAlex ID: A5025882503
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
2025 · Reshmi Nair, Veena Somasundaram, et al. · Frontiers in Immunology · 106
PDF
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
2017 · Usha Bughani, Arindam Saha, et al. · PLoS ONE · 55
BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Cancer Research · 40
PDF
874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy
2021 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
2018 · Usha Bughani, Arindam Saha, et al. · PLoS ONE · 3
PDF
Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2025 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
1180 Dual targeting of TGF-β and EGFR with ficerafusp alfa shows superior anti-tumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer
2025 · Anshu Kuriakose, Reshmi Nair, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth
2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth
2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth
2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Abstract 6339: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Cancer Research
1368 A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
2022 · Pradip Nair, Arvind Goswamy, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 15
Citation count: 207
H-index: 3
I10-index: 3
Year
Topic
Type